Michael Barbella, Managing Editor04.03.24
iCAD Inc. has appointed Michael J. Doyle to its Board of Directors.
Doyle is a seasoned technology and healthcare executive with more than 35 years of experience. He is currently CEO of Spire Health, a healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire, along with Doyle’s recent companies, all achieved measurable patient and health outcome improvement by harnessing the power of artificial intelligence and machine learning. He has been a CEO and director of seven healthcare companies.
“We are thrilled to welcome Mr. Doyle to the iCAD Board of Directors,” iCAD Chairman/President/CEO Dana Brown said. “His extensive experience and expertise in the healthcare and technology industries will be invaluable as we continue to develop and deliver innovative AI-powered solutions that improve patient outcomes around the world.”
Doyle has also been appointed to numerous private, not for profit, and public company boards. He brings vast experience in healthcare technology and business strategy to iCAD's board.
“I am eager to support iCAD’s management team and directors. Early detection is a critical path to better cancer outcomes and iCAD’s AI-powered technology is at the forefront of innovation in the space,” Doyle stated.
iCAD Inc. develops clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H.., iCAD’s ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation. The ProFound Breast Health Suite is cleared by the U.S. Food and Drug Administration (FDA) and has received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, ProFound is available in more than 50 countries.
Doyle is a seasoned technology and healthcare executive with more than 35 years of experience. He is currently CEO of Spire Health, a healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire, along with Doyle’s recent companies, all achieved measurable patient and health outcome improvement by harnessing the power of artificial intelligence and machine learning. He has been a CEO and director of seven healthcare companies.
“We are thrilled to welcome Mr. Doyle to the iCAD Board of Directors,” iCAD Chairman/President/CEO Dana Brown said. “His extensive experience and expertise in the healthcare and technology industries will be invaluable as we continue to develop and deliver innovative AI-powered solutions that improve patient outcomes around the world.”
Doyle has also been appointed to numerous private, not for profit, and public company boards. He brings vast experience in healthcare technology and business strategy to iCAD's board.
“I am eager to support iCAD’s management team and directors. Early detection is a critical path to better cancer outcomes and iCAD’s AI-powered technology is at the forefront of innovation in the space,” Doyle stated.
iCAD Inc. develops clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H.., iCAD’s ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation. The ProFound Breast Health Suite is cleared by the U.S. Food and Drug Administration (FDA) and has received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, ProFound is available in more than 50 countries.